Tumor necrosis factor inhibitors
The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions.
1. A method of treating rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising a compound having a structure of Formula (III), or a pharmaceutically acceptable salt thereof:
wherein
R 10 , R 11 , and R 12 are each independently hydrogen, alkyl, hydroxyl, alkoxy, NR 13 R 14 , halogen, nitro, cyano, borono, aryl, aryloxy, benzyl, —(CH 2 ) n COOR 15 , —O(CH 2 ) n COOR 16 , —OC(O)R 17 , —CR 18 ═NOH, —CR 19 R 20 NHOH, —SO 3 H, —SO 2 R 21 , —SO 2 NHR 22 , —O(CH 2 ) m OR 23 , —C(OH)═NOH, —C(O)NR 24 OH, CHR 25 N(COR 26 )OH, or C(O)R 27 ;
R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , and R 26 are each independently hydrogen, alkyl, or aryl, and R 27 is alkyl or aryl; and
n and m are independently 0, 1, 2, 3, 4, 5, or 6;
and pharmaceutically acceptable excipient.
2. The method of claim 1 , wherein R 10 , R 11 , and R 12 are each independently hydrogen, C 1-6 saturated alkyl, C 3-7 cycloalkyl, hydroxyl, C 1-6 alkoxy, —NR 13 R 14 , halogen, nitro, cyano, borono, phenyl, benzyl, benzoyl, phenoxy, benzyloxy, —(CH 2 ) n COOR 15 , —O(CH 2 ) n COOR 16 , —OC(O)R 17 , —CH═NOH, —CH 2 NHOH, —SO 3 H, —SO 2 CH 3 , —SO 2 NHR 22 , —O(CH 2 ) m OR 23 , —C(OH)═NOH, —C(O)NR 24 OH, —CHR 25 N(COR 26 )OH, or C(O)R 27 .
3. The method of claim 2 , wherein R 10 , R 11 , and R 12 are each independently hydroxyl, —OC(O)H, —OC(O)CH 3 , halogen, or nitro.
4. The method of claim 3 , wherein R 10 and R 11 are each independently hydroxyl, —OC(O)CH 3 , and halogen; and R 12 is nitro.
5. The method of claim 1 , wherein the compound is:
6. The method of claim 1 , wherein the pharmaceutical composition is in the form of a capsule or tablet.
7. The method of claim 6 , wherein the capsule or tablet contains the compound having a structure of Formula (III) in an amount in a range of about 25 mg to about 200 mg.
8. A method of treating rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis comprising administering to a patient in need of such treatment an effective amount of a compound having a structure of Formula (III), or a pharmaceutically acceptable salt thereof:
wherein
R 10 , R 11 , and R 12 are each independently hydrogen, alkyl, hydroxyl, alkoxy, NR 13 R 14 , halogen, nitro, cyano, borono, aryl, aryloxy, benzyl, —(CH 2 ) n COOR 15 , —O(CH 2 ) n COOR 16 , —OC(O)R 17 , —CR 18 ═NOH, —CR 19 R 20 NHOH, —SO 3 H, —SO 2 R 21 , —SO 2 NHR 22 , —O(CH 2 ) m OR 23 , —C(OH)═NOH, —C(O)NR 24 OH, CHR 25 N(COR 26 )OH, or C(O)R 27 ;
R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , and R 26 are each independently hydrogen, alkyl, or aryl, and R 27 is alkyl or aryl; and
n and m are independently 0, 1, 2, 3, 4, 5, or 6.
9. The method of claim 8 , wherein R 10 , R 11 , and R 12 are each independently hydrogen, C 1-6 saturated alkyl, C 3-7 cycloalkyl, hydroxyl, C 1-6 alkoxy, —NR 13 R 14 , halogen, nitro, cyano, borono, phenyl, benzyl, benzoyl, phenoxy, benzyloxy, —(CH 2 ) n COOR 15 , —O(CH 2 ) n COOR 16 , —OC(O)R 17 , —CH═NOH, —CH 2 NHOH, —SO 3 H, —SO 2 CH 3 , —SO 2 NHR 22 , —O(CH 2 ) m OR 23 , —C(OH)═NOH, —C(O)NR 24 OH, —CHR 25 N(COR 26 )OH, or C(O)R 27 .
10. The method of claim 8 , wherein R 10 , R 11 , and R 12 are each independently hydroxyl, —OC(O)H, —OC(O)CH 3 , halogen, or nitro.
11. The method of claim 10 , wherein R 10 and R 11 are each independently hydroxyl, —OC(O)CH 3 , and halogen; and R 12 is nitro.
12. The method of claim 8 , wherein the compound is: